CSM Advisors LLC Sells 42,400 Shares of Gilead Sciences, Inc. $GILD

CSM Advisors LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 73.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 15,075 shares of the biopharmaceutical company’s stock after selling 42,400 shares during the period. CSM Advisors LLC’s holdings in Gilead Sciences were worth $1,674,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $26,000. Howard Hughes Medical Institute bought a new position in Gilead Sciences during the 2nd quarter worth approximately $30,000. MTM Investment Management LLC grew its position in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares during the last quarter. Kilter Group LLC purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $33,000. Finally, Millstone Evans Group LLC increased its stake in Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 118 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Up 0.2%

Shares of Gilead Sciences stock opened at $145.21 on Tuesday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The company has a market cap of $180.27 billion, a P/E ratio of 21.45, a PEG ratio of 1.90 and a beta of 0.36. The company’s fifty day simple moving average is $141.16 and its two-hundred day simple moving average is $127.19.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is presently 48.45%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Cantor Fitzgerald increased their price objective on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Wolfe Research lifted their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Sanford C. Bernstein reiterated an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a report on Wednesday, February 11th. Morgan Stanley increased their price target on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Finally, Barclays assumed coverage on shares of Gilead Sciences in a report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price target on the stock. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the transaction, the insider owned 120,288 shares in the company, valued at approximately $18,577,278.72. This represents a 18.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the completion of the transaction, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This represents a 1.76% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 303,280 shares of company stock valued at $43,203,470. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.